Total
0
Shares
EMVision Medical Devices (ASX:EMV) - CEO, Ron Weinberger
CEO, Ron Weinberger
Source: EMVision
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • EmVision Medical Devices (EMV) has taken another step in its Breakthrough Device Designation (BDD) application
  • The company receives feedback on its BDD application from the FDA, which suggested that although preliminary evidence supports the technology’s potential to differentiate and localise haemorrhagic and ischemic stroke, additional clinical data is required
  • As a result of this, the BDD has not yet been granted to Emvision, but the company says it will continue to pursue it once clinical data is available
  • EmVision Medical Devices is trading 3.91 per cent down at $2.95 at 10:47 am AEDT

EmVision Medical Devices (EMV) has taken another step it its Breakthrough Device Designation (BDD) application.

The company received feedback on its BDD application from the Food and Drug Administration (FDA), which suggested preliminary evidence supports the potential of the technology to differentiate and localise haemorrhagic and ischemic stroke.

However, the FDA responded that additional clinical study data is required, which EmVision will need to generate through further clinical development. As a result of this, the BDD has not yet been granted.

EMVision CEO, Ron Weinberger said the company was grateful for the feedback received from the FDA.

“Our pathway to FDA marketing authorisation remains unchanged, as does our preparation for expanded clinical studies and future commercialisation,” Dr Weinberger said.  

The US Food and Drug Administration (FDA) BDD is a discretionary program that offers priority review and interactive communication across the device development and validation path.  EmVision said it would continue to further pursue the BDD once the required clinical data is available.

Meanwhile, EMVision’s pursuit of the FDA De Novo regulatory marketing authorisation pathway for its first generation portable brain scanner product remains unaffected.

The company also said it expected to complete enrolment of the additional 20 patient datasets of its pilot trial this month, with processing and reporting of these additional datasets anticipated this quarter.

EmVision Medical Devices was trading 3.91 per cent down at $2.95 at 10:47 am AEDT.

EMV by the numbers
More From The Market Herald

" Recce Pharmaceuticals (ASX:RCE) receives positive safety data from second cohort of Phase I Clinical Trial

Recce Pharmaceuticals (ASX:RCE) has released positive safety data from its second cohort of subjects for its…
Virtus Health (ASX:VRT) - CEO & Managing Director, Kate Munnings

" Virtus Health (ASX:VRT) has non-urgent elective surgeries suspended in NSW & VIC

Virtus Health (ASX:VRT) has had its non-urgent elective surgeries suspended in NSW and Victoria as the…

" Creso Pharma (ASX:CPH) appoints William Lay as CEO & MD

Creso Pharma (ASX:CPH) has strengthened its board with the appointment of William Lay as CEO and…

" Monash IVF Group (ASX:MVF) suspends certain procedures in Victoria

Following new health orders in Victoria, Monash IVF Group (ASX:MVF) says non-urgent surgery protocols will disrupt…